ABSCIENCES (EPA:AB) Half-year report on AB Science’s liquidity contract
Transparency directive : regulatory news
05/01/2011 17:45
Click here to download pdf version
Paris, January 5th, 2010 - 5.45 pm
Half-year report on AB Science's liquidity contract
Under the liquidity contract entrusted by AB Science to SG Securities (Paris),
the following assets appeared on the liquidity account at 31 December 2010:
- 7 506 shares
- 17.419,35EUR
For information, the following assets appeared on the liquidity account at
23 June 2010:
- 150 shares
- 98.267,50 EUR
About AB Science
Founded in 2001, AB Science is a pharmaceutical company specializing in the
research, development and commercialization of protein kinase inhibitors (PKIs),
a new class of targeted molecules whose action is to modify signalling pathways
within cells. Through these PKIs, the Company targets diseases with high unmet
medical needs (cancer, inflammatory diseases and central nervous system
diseases), in both human and veterinary medicines. Thanks to its extensive
research and development capabilities, AB Science has its own portfolio of
molecules. Masitinib, a lead compound, has already been registered in veterinary
medicine in Europe and is pursuing three on-going phases 3 in human medicine in
pancreatic cancer, GIST and mastocytosis.
AB Science is listed on NYSE Euronext Paris (Compartment B) - ISIN: FR0010557264
- Ticker: AB
Further information is available on AB Science's website: www.ab-science.com
Financial Communication & Press Relations
Citigate Contacts Citigate Dewe Rogerson :
Dewe Rogerson Agnès Villeret - Tel: +33 1 53 32 78 95 -
agnes.villeret@citigate.fr